{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,23]],"date-time":"2026-05-23T04:05:37Z","timestamp":1779509137732,"version":"3.53.1"},"reference-count":134,"publisher":"International Research and Cooperation Association for Bio & Socio-Sciences Advancement (IRCA-BSSA)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["BST"],"published-print":{"date-parts":[[2026,4,30]]},"DOI":"10.5582\/bst.2026.01032","type":"journal-article","created":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T22:09:02Z","timestamp":1774390142000},"page":"160-177","source":"Crossref","is-referenced-by-count":0,"title":["Characteristics and management of constitutional indocyanine green excretory defect"],"prefix":"10.5582","volume":"20","author":[{"given":"Jiaao","family":"Wang","sequence":"first","affiliation":[{"name":"Division of Liver Surgery, Department of General Surgery, West China Hospital, Sichuan University, Chengdu, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziqi","family":"Hou","sequence":"additional","affiliation":[{"name":"Division of Liver Surgery, Department of General Surgery, West China Hospital, Sichuan University, Chengdu, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Ji","sequence":"additional","affiliation":[{"name":"Division of Liver Surgery, Department of General Surgery, West China Hospital, Sichuan University, Chengdu, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ding","family":"Hu","sequence":"additional","affiliation":[{"name":"Division of Liver Surgery, Department of General Surgery, West China Hospital, Sichuan University, Chengdu, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changlong","family":"Wei","sequence":"additional","affiliation":[{"name":"Division of Liver Surgery, Department of General Surgery, West China Hospital, Sichuan University, Chengdu, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhihong","family":"Zhang","sequence":"additional","affiliation":[{"name":"Division of Liver Surgery, Department of General Surgery, West China Hospital, Sichuan University, Chengdu, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanzhi","family":"Zhou","sequence":"additional","affiliation":[{"name":"Division of Liver Surgery, Department of General Surgery, West China Hospital, Sichuan University, Chengdu, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haichuan","family":"Wang","sequence":"additional","affiliation":[{"name":"Division of Liver Surgery, Department of General Surgery, West China Hospital, Sichuan University, Chengdu, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiwei","family":"Huang","sequence":"additional","affiliation":[{"name":"Division of Liver Surgery, Department of General Surgery, West China Hospital, Sichuan University, Chengdu, China."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"3542","reference":[{"key":"1","unstructured":"1. Dong J, Zheng S, Chen X, Dou K, Fan J, Bie P, Geng X, Lv W. Consensus on evaluation of hepatic functional reserve before hepatectomy (2011 edition). Chin J Dig Surg. 2011; 10:20-25."},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Fan ST. Liver functional reserve estimation: state of the art and relevance for local treatments: the Eastern perspective. J Hepatobiliary Pancreat Sci. 2010; 17:380-384.","DOI":"10.1007\/s00534-009-0229-9"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Durand F, Valla D. Assessment of prognosis of cirrhosis. Semin Liver Dis. 2008; 28:110-122.","DOI":"10.1055\/s-2008-1040325"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Garcea G, Ong SL, Maddern GJ. Predicting liver failure following major hepatectomy. Dig Liver Dis. 2009; 41:798-806.","DOI":"10.1016\/j.dld.2009.01.015"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Hoekstra LT, de Graaf W, Nibourg GA, Heger M, Bennink RJ, Stieger B, van Gulik TM. Physiological and biochemical basis of clinical liver function tests: a review. Ann Surg. 2013; 257:27-36.","DOI":"10.1097\/SLA.0b013e31825d5d47"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Woreta TA, Alqahtani SA. Evaluation of abnormal liver tests. Med Clin North Am. 2014; 98:1-16.","DOI":"10.1016\/j.mcna.2013.09.005"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Kaibori M, Matsui K, Shimada M, Kubo S, Hasegawa K. Update on perioperative management of patients undergoing surgery for liver cancer. Ann Gastroenterol Surg. 2022; 6:344-354.","DOI":"10.1002\/ags3.12529"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Lau H, Man K, Fan ST, Yu WC, Lo CM, Wong J. Evaluation of preoperative hepatic function in patients with hepatocellular carcinoma undergoing hepatectomy. Br J Surg. 1997; 84:1255-1259.","DOI":"10.1046\/j.1365-2168.1997.02770.x"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Cherrick GR, Stein SW, Leevy CM, Davidson CS. Indocyanine green: observations on its physical properties, plasma decay, and hepatic extraction. J Clin Invest. 1960; 39:592-600.","DOI":"10.1172\/JCI104072"},{"key":"10","unstructured":"10. Caesar J, Shaldon S, Chiandussi L, Guevara L, Sherlock S. The use of indocyanine green in the measurement of hepatic blood flow and as a test of hepatic function. Clin Sci. 1961; 21:43-57."},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Miyagawa S, Makuuchi M, Kawasaki S, Kakazu T. Criteria for safe hepatic resection. Am J Surg. 1995; 169:589-594.","DOI":"10.1016\/S0002-9610(99)80227-X"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Namihisa T, Nambu M, Kobayashi N, Kuroda H. The constitutional indocyanine green excretory defect--report of four cases. Gastroenterol Jpn. 1975; 10:70-76.","DOI":"10.1007\/BF02775925"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Okuda K, Ohkubo H, Musha H, Kotoda K, Abe H, Tanikawa K. Marked delay in indocyanine green plasma clearance with a near-normal bromosulphophthalein retention test: a constitutional abnormality? Gut. 1976; 17:588-594.","DOI":"10.1136\/gut.17.8.588"},{"key":"14","unstructured":"14. Namihisa T, Nambu M, Kobayashi N, Kuroda H. Nine cases with marked retention of indocyanine green test and normal sulfobromophthalein test without abnormal liver histology: constitutional indocyanine green excretory defect. Hepatogastroenterology. 1981; 28:6-12."},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Ott P. Hepatic elimination of indocyanine green with special reference to distribution kinetics and the influence of plasma protein binding. Pharmacol Toxicol. 1998; 83 Suppl 2:1-48.","DOI":"10.1111\/j.1600-0773.1998.tb01945.x"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. de Graaf W, H\u00e4usler S, Heger M, van Ginhoven TM, van Cappellen G, Bennink RJ, Kullak-Ublick GA, Hesselmann R, van Gulik TM, Stieger B. Transporters involved in the hepatic uptake of (99m)Tc-mebrofenin and indocyanine green. J Hepatol. 2011; 54:738-745.","DOI":"10.1016\/j.jhep.2010.07.047"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Huet PM, Du Reau A, Marleau D. Arterial and portal blood supply in cirrhosis: a functional evaluation. Gut. 1979; 20:792-796.","DOI":"10.1136\/gut.20.9.792"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Kwon AH, Ha-Kawa SK, Uetsuji S, Inoue T, Matsui Y, Kamiyama Y. Preoperative determination of the surgical procedure for hepatectomy using technetium-99m-galactosyl human serum albumin (99mTc-GSA) liver scintigraphy. Hepatology. 1997; 25:426-429.","DOI":"10.1002\/hep.510250228"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Cui Y, K\u00f6nig J, Leier I, Buchholz U, Keppler D. Hepatic uptake of bilirubin and its conjugates by the human organic anion transporter SLC21A6. J Biol Chem. 2001; 276:9626-9630.","DOI":"10.1074\/jbc.M004968200"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Geier A, Wagner M, Dietrich CG, Trauner M. Principles of hepatic organic anion transporter regulation during cholestasis, inflammation and liver regeneration. Biochim Biophys Acta. 2007; 1773:283-308.","DOI":"10.1016\/j.bbamcr.2006.04.014"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Adachi Y, Yamamoto T, Onishi S, Tanaka S, Wakisaka G. The discrepancy between plasma clearance tests of indocyanine green (ICG) and sulfobromophthalein (BSP): --report of cases and a study of ICG-binding pattern of serum proteins. Gastroenterol Jpn. 1976; 11:75-87.","DOI":"10.1007\/BF02776703"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Takase S, Takada A, Matsuda Y. Studies on the pathogenesis of the constitutional excretory defect of indocyanine green. Gastroenterol Jpn. 1982; 17:301-309.","DOI":"10.1007\/BF02774575"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Taketazu F, Sanada I, Ngamatsu N, Mukai R, Suetomo Y, Toyoda N, Takada M, Hida K, Kubota K, Maezawa M. A case of hereditary elliptocytosis associated with constitutional indocyanine green excretory defect. Jpn J Med. 1984; 23:139-143.","DOI":"10.2169\/internalmedicine1962.23.139"},{"key":"24","unstructured":"24. Gotoh K, Konaga E, Takeuchi H, Mano S, Kohno H. A case of biliary cystadenocarcinoma arising in the liver with a congenital retention of indocyanine green. Acta Med Okayama. 1992; 46:389-393."},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Ikejima K, Ichikawa S, Kitamura T, Watanabe S, Hirose M, Yokoi Y, Uchida S, Oide H, Suzuki H, Kitami N. Marked retention of indocyanine green and sulfobromophthalein with chronic persistent hepatitis. J Gastroenterol Hepatol. 1993; 8:489-494.","DOI":"10.1111\/j.1440-1746.1993.tb01554.x"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Nambu M, Namihisa T. Hepatic transport of serum bilirubin, bromsulfophthalein, and indocyanine green in patients with congenital non-hemolytic hyperbilirubinemia and patients with constitutional indocyanine green excretory defect. J Gastroenterol. 1996; 31:228-236.","DOI":"10.1007\/BF02389522"},{"key":"27","unstructured":"27. Hanazaki K, Wakabayashi M, Makiuchi A, Igarashi J, Sodeyama H, Wada S, Amano J. Hepatectomy of cavernous hemangioma with constitutional indocyanine green excretory defect. Hepatogastroenterology. 2000; 47:1719-1721."},{"key":"28","unstructured":"28. Yamanaka N, Shimizu S, Chijiiwa K, Nishiyama K, Noshiro H, Yamaguchi K, Tanaka M. Hepatectomy and marked retention of indocyanine green and bromosulfophtalein. Hepatogastroenterology. 2001; 48:1450-1452."},{"key":"29","doi-asserted-by":"crossref","unstructured":"29. Kadono J, Kumemura H, Nishida S, Nakamura N, Gejima K, Nakajo M, Tsuchimochi S, Matsumoto J, Hamada N, Sakata R. 99mTc-DTPA-galactosyl-human-serum-albumin liver scintigraphy for evaluating hepatic functional reserve before hepatectomy in a patient with indocyanine green excretory defect: report of a case. Surg Today. 2006; 36:481-484.","DOI":"10.1007\/s00595-005-3181-6"},{"key":"30","unstructured":"30. Maeda H, Okabayashi T, Kobayashi M, Sugimoto T, Namikawa T, Okamoto K, Araki K. Hepatectomy for hepatocellular carcinoma with indocyanine green excretory defect: a case report. Hepatogastroenterology. 2007; 54:1810-1812."},{"key":"31","doi-asserted-by":"crossref","unstructured":"31. Aoki H, Morihiro T, Arata T, Kanaya N, Takeda S, Ninomiya T, Seita M, Katsuda K, Tanakaya K, Takeuchi H. Hepatectomy in a hepatocellular carcinoma case with Dubin-Johnson syndrome and indocyanine green excretory defect. Clin J Gastroenterol. 2013; 6:69-74.","DOI":"10.1007\/s12328-012-0347-9"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32. Imada S, Kobayashi T, Kitao A, Matsui O, Hashimoto M, Ide K, Ishiyama K, Arihiro K, Tashiro H, Ohdan H. Central bisectionectomy for hepatocellular carcinoma in a patient with indocyanine green excretory defect associated with reduced expression of the liver transporter. Surg Case Rep. 2016; 2:89.","DOI":"10.1186\/s40792-016-0216-8"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33. Kagawa T, Adachi Y, Hashimoto N, Mitsui H, Ohashi T, Yoneda M, Hasegawa I, Hirose S, Tsuruya K, Anzai K, Mine T. Loss of organic anion transporting polypeptide 1B3 function causes marked delay in indocyanine green clearance without any clinical symptoms. Hepatology. 2017; 65:1065-1068.","DOI":"10.1002\/hep.28950"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34. Nakatake R, Ishizaki M, Miyasaka C, Matsui K, Kaibori M. Hepatectomy in a case of hepatocellular carcinoma with constitutional indocyanine green excretory defect. Int J Surg Case Rep. 2018; 53:231-234.","DOI":"10.1016\/j.ijscr.2018.10.074"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35. Sumiyoshi T, Okabayashi T, Negoro Y, Hata Y, Noda Y, Sui K, Iwata J, Matsumoto M. (99m)Tc-GSA SPECT\/CT fusion imaging for hepatectomy candidates with extremely deteriorated ICG value. Jpn J Radiol. 2018; 36:537-543.","DOI":"10.1007\/s11604-018-0753-0"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36. Anzai K, Tsuruya K, Morimachi M, Arase Y, Hirose S, Hirabayashi K, Adachi Y, Kagawa T. The Impact of a Heterozygous SLCO1B3 Null Variant on the Indocyanine Green Retention Test. J Pharm Sci. 2020; 109:3206-3209.","DOI":"10.1016\/j.xphs.2020.06.020"},{"key":"37","doi-asserted-by":"crossref","unstructured":"37. Masuoka S, Nasu K, Takahashi H, Kitao A, Sakai M, Ishiguro T, Saida T, Minami M. Impaired lesion detectability on gadoxetic acid-enhanced MR imaging in indocyanine green excretory defect: case series of three patients. Jpn J Radiol. 2020; 38:997-1003.","DOI":"10.1007\/s11604-020-00991-9"},{"key":"38","doi-asserted-by":"crossref","unstructured":"38. Tanimoto M, Nishioka Y, Inagaki Y, Kokudo T, Ishizawa T, Arita J, Akamatsu N, Kaneko J, Hasegawa K. Genetic alteration of SLCO1B3 defines constitutional indocyanine green excretory defect in patients who underwent hepatectomy. Hepatol Res. 2024.","DOI":"10.1111\/hepr.14099"},{"key":"39","doi-asserted-by":"crossref","unstructured":"39. Morikawa T, Wakui Y, Hasegawa Y, Sugisawa N, Kimura S, Hirashima T, Kinouchi M, Iwasashi H. Laparoscopic Anatomical Liver Resection for the Patients With Constitutional Indocyanine Green Excretory Defect: A Case Report. Asian J Endosc Surg. 2025; 18:e13415.","DOI":"10.1111\/ases.13415"},{"key":"40","doi-asserted-by":"crossref","unstructured":"40. Liu W, Chen LJ, Jiang Y, Xu LJ, Qiu X. Hepatocellular carcinoma with indocyanine green excretory defect: a case report and review of the literature. J Int Med Res. 2021; 49:3000605211004025.","DOI":"10.1177\/03000605211004025"},{"key":"41","doi-asserted-by":"crossref","unstructured":"41. Ishigami Y, Masuzawa M, Miyoshi E, Kato M, Tamura K, Kanda M, Awazu K, Taniguchi K, Kurita M, Hayashi N. Clinical applications of ICG Finger Monitor in patients with liver disease. J Hepatol. 1993; 19:232-240.","DOI":"10.1016\/S0168-8278(05)80577-X"},{"key":"42","doi-asserted-by":"crossref","unstructured":"42. Soderquist C, Bagg A. Hereditary elliptocytosis. Blood. 2013; 121:3066.","DOI":"10.1182\/blood-2012-09-457788"},{"key":"43","unstructured":"43. Kawasaki H, Kimura N, Irisa T, Hirayama C. Dye clearance studies in Rotor&apos;s syndrome. Am J Gastroenterol. 1979; 71:380-388."},{"key":"44","doi-asserted-by":"crossref","unstructured":"44. Makuuchi M, Kosuge T, Takayama T, Yamazaki S, Kakazu T, Miyagawa S, Kawasaki S. Surgery for small liver cancers. Semin Surg Oncol. 1993; 9:298-304.","DOI":"10.1002\/ssu.2980090404"},{"key":"45","doi-asserted-by":"crossref","unstructured":"45. Tanimoto A, Lee JM, Murakami T, Huppertz A, Kudo M, Grazioli L. Consensus report of the 2nd International Forum for Liver MRI. Eur Radiol. 2009; 19 Suppl 5:S975-989.","DOI":"10.1007\/s00330-009-1624-y"},{"key":"46","doi-asserted-by":"crossref","unstructured":"46. Huppertz A, Balzer T, Blakeborough A, Breuer J, Giovagnoni A, Heinz-Peer G, Laniado M, Manfredi RM, Mathieu DG, Mueller D, Reimer P, Robinson PJ, Strotzer M, Taupitz M, Vogl TJ. Improved detection of focal liver lesions at MR imaging: multicenter comparison of gadoxetic acid-enhanced MR images with intraoperative findings. Radiology. 2004; 230:266-275.","DOI":"10.1148\/radiol.2301020269"},{"key":"47","doi-asserted-by":"crossref","unstructured":"47. Tsurusaki M, Sofue K, Murakami T. Current evidence for the diagnostic value of gadoxetic acid-enhanced magnetic resonance imaging for liver metastasis. Hepatol Res. 2016; 46:853-861.","DOI":"10.1111\/hepr.12646"},{"key":"48","doi-asserted-by":"crossref","unstructured":"48. Nigam SK, Bush KT, Martovetsky G, Ahn SY, Liu HC, Richard E, Bhatnagar V, Wu W. The organic anion transporter (OAT) family: A systems biology perspective. Physiol Rev. 2015; 95:83-123.","DOI":"10.1152\/physrev.00025.2013"},{"key":"49","doi-asserted-by":"crossref","unstructured":"49. Kroll T, Prescher M, Smits SHJ, Schmitt L. Structure and Function of Hepatobiliary ATP Binding Cassette Transporters. Chem Rev. 2021; 121:5240-5288.","DOI":"10.1021\/acs.chemrev.0c00659"},{"key":"50","doi-asserted-by":"crossref","unstructured":"50. Tan X, Xiang Y, Shi J, Chen L, Yu D. Targeting NTCP for liver disease treatment: A promising strategy. J Pharm Anal. 2024; 14:100979.","DOI":"10.1016\/j.jpha.2024.100979"},{"key":"51","doi-asserted-by":"crossref","unstructured":"51. Hagenbuch B, Stieger B, Locher KP. Organic anion transporting polypeptides: Pharmacology, toxicology, structure, and transport mechanisms. Pharmacol Rev. 2025; 77:100023.","DOI":"10.1016\/j.pharmr.2024.100023"},{"key":"52","doi-asserted-by":"crossref","unstructured":"52. Sekine T, Cha SH, Endou H. The multispecific organic anion transporter (OAT) family. Pflugers Arch. 2000; 440:337-350.","DOI":"10.1007\/s004240000297"},{"key":"53","doi-asserted-by":"crossref","unstructured":"53. Hagenbuch B, Meier PJ. Organic anion transporting polypeptides of the OATP\/ SLC21 family: phylogenetic classification as OATP\/ SLCO superfamily, new nomenclature and molecular\/functional properties. Pflugers Arch. 2004; 447:653-665.","DOI":"10.1007\/s00424-003-1168-y"},{"key":"54","doi-asserted-by":"crossref","unstructured":"54. K\u00f6nig J , Sei thel A, Gradhand U, Fromm MF. Pharmacogenomics of human OATP transporters. Naunyn Schmiedebergs Arch Pharmacol. 2006; 372:432-443.","DOI":"10.1007\/s00210-006-0040-y"},{"key":"55","doi-asserted-by":"crossref","unstructured":"55. Ho RH, Tirona RG, Leake BF, Glaeser H, Lee W, Lemke CJ, Wang Y, Kim RB. Drug and bile acid transporters in rosuvastatin hepatic uptake: function, expression, and pharmacogenetics. Gastroenterology. 2006; 130:1793-1806.","DOI":"10.1053\/j.gastro.2006.02.034"},{"key":"56","doi-asserted-by":"crossref","unstructured":"56. Vaz FM, Paulusma CC, Huidekoper H, de Ru M, Lim C, Koster J, Ho-Mok K, Bootsma AH, Groen AK, Schaap FG, Oude Elferink RP, Waterham HR, Wanders RJ. Sodium taurocholate cotransporting polypeptide (SLC10A1) deficiency: conjugated hypercholanemia without a clear clinical phenotype. Hepatology. 2015; 61:260-267.","DOI":"10.1002\/hep.27240"},{"key":"57","doi-asserted-by":"crossref","unstructured":"57. van de Steeg E, Str\u00e1neck\u00fd V, Hartmannov\u00e1 H, <i>et al<\/i>. Complete OATP1B1 and OATP1B3 deficiency causes human Rotor syndrome by interrupting conjugated bilirubin reuptake into the liver. J Clin Invest. 2012; 122:519-528.","DOI":"10.1172\/JCI59526"},{"key":"58","doi-asserted-by":"crossref","unstructured":"58. V\u00edtek L, Tiribelli C. Gilbert&apos;s syndrome revisited. J Hepatol. 2023; 79:1049-1055.","DOI":"10.1016\/j.jhep.2023.06.004"},{"key":"59","doi-asserted-by":"crossref","unstructured":"59. Martin JF, Vierling JM, Wolkoff AW, Scharschmidt BF, Vergalla J, Waggoner JG, Berk PD. Abnormal hepatic transport of indocyanine green in Gilbert&apos;s syndrome. Gastroenterology. 1976; 70:385-391.","DOI":"10.1016\/S0016-5085(76)80151-5"},{"key":"60","doi-asserted-by":"crossref","unstructured":"60. Fahrmayr C, Fromm MF, K\u00f6nig J. Hepatic OATP and OCT uptake transporters: their role for drug-drug interactions and pharmacogenetic aspects. Drug Metab Rev. 2010; 42:380-401.","DOI":"10.3109\/03602530903491683"},{"key":"61","doi-asserted-by":"crossref","unstructured":"61. Alam K, Crowe A, Wang X, Zhang P, Ding K, Li L, Yue W. Regulation of Organic Anion Transporting Polypeptides (OATP) 1B1- and OATP1B3-Mediated Transport: An Updated Review in the Context of OATP-Mediated Drug-Drug Interactions. Int J Mol Sci. 2018; 19:855.","DOI":"10.3390\/ijms19030855"},{"key":"62","doi-asserted-by":"crossref","unstructured":"62. Hagenbuch B, Stieger B. The SLCO (former SLC21) superfamily of transporters. Mol Aspects Med. 2013; 34:396-412.","DOI":"10.1016\/j.mam.2012.10.009"},{"key":"63","doi-asserted-by":"crossref","unstructured":"63. Sato T, Yamaguchi H, Kogawa T, Abe T, Mano N. Organic anion transporting polypeptides 1B1 and 1B3 play an important role in uremic toxin handling and drug-uremic toxin interactions in the liver. J Pharm Pharm Sci. 2014; 17:475-484.","DOI":"10.18433\/J3M89Q"},{"key":"64","doi-asserted-by":"crossref","unstructured":"64. Ikema S, Takumi S, Maeda Y, Kurimoto T, Bohda S, Chigwechokha PK, Sugiyama Y, Shiozaki K, Furukawa T, Komatsu M. Okadaic acid is taken-up into the cells mediated by human hepatocytes transporter OATP1B3. Food Chem Toxicol. 2015; 83:229-236.","DOI":"10.1016\/j.fct.2015.06.006"},{"key":"65","doi-asserted-by":"crossref","unstructured":"65. Schulte RR, Ho RH. Organic Anion Transporting Polypeptides: Emerging Roles in Cancer Pharmacology. Mol Pharmacol. 2019; 95:490-506.","DOI":"10.1124\/mol.118.114314"},{"key":"66","doi-asserted-by":"crossref","unstructured":"66. Wang J, Gan C, Qi X, Lebre MC, Schinkel AH. Human organic anion transporting polypeptide (OATP) 1B3 and mouse OATP1A\/1B affect liver accumulation of Ochratoxin A in mice. Toxicol Appl Pharmacol. 2020; 401:115072.","DOI":"10.1016\/j.taap.2020.115072"},{"key":"67","doi-asserted-by":"crossref","unstructured":"67. Wissler EH. Identifying a long standing error in single-bolus determination of the hepatic extraction ratio for indocyanine green. Eur J Appl Physiol. 2011; 111:641- 646.","DOI":"10.1007\/s00421-010-1678-1"},{"key":"68","doi-asserted-by":"crossref","unstructured":"68. Kaibori M, Ha-Kawa SK, Maehara M, Ishizaki M, Matsui K, Sawada S, Kwon AH. Usefulness of Tc-99m-GSA scintigraphy for liver surgery. Ann Nucl Med. 2011; 25:593-602.","DOI":"10.1007\/s12149-011-0520-0"},{"key":"69","doi-asserted-by":"crossref","unstructured":"69. Stockert RJ, Morell AG. Hepatic binding protein: the galactose-specific receptor of mammalian hepatocytes. Hepatology. 1983; 3:750-757.","DOI":"10.1002\/hep.1840030520"},{"key":"70","doi-asserted-by":"crossref","unstructured":"70. Okabayashi T, Shima Y, Morita S, Shimada Y, Sumiyoshi T, Sui K, Iwata J, Iiyama T. Liver Function Assessment Using Technetium 99m-Galactosyl Single-Photon Emission Computed Tomography\/CT Fusion Imaging: A Prospective Trial. J Am Coll Surg. 2017; 225:789-797.","DOI":"10.1016\/j.jamcollsurg.2017.08.021"},{"key":"71","doi-asserted-by":"crossref","unstructured":"71. Sawamura T, Nakada H, Hazama H, Shiozaki Y, Sameshima Y, Tashiro Y. Hyperasialoglycoproteinemia in patients with chronic liver diseases and\/or liver cell carcinoma. Asialoglycoprotein receptor in cirrhosis and liver cell carcinoma. Gastroenterology. 1984; 87:1217-1221.","DOI":"10.1016\/0016-5085(84)90185-9"},{"key":"72","unstructured":"72. Kondo M. Usefulness of 99mTc-GSA scintigraphy for estimation of residual hepatic functions and postoperative changes of HH15 and LHL15. Kaku Igaku. 2001; 38:191-200."},{"key":"73","doi-asserted-by":"crossref","unstructured":"73. Iimuro Y, Kashiwagi T, Yamanaka J, Hirano T, Saito S, Sugimoto T, Watanabe S, Kuroda N, Okada T, Asano Y, Uyama N, Fujimoto J. Preoperative estimation of asialoglycoprotein receptor expression in the remnant liver from CT\/99mTc-GSA SPECT fusion images correlates well with postoperative liver function parameters. J Hepatobiliary Pancreat Sci. 2010; 17:673-681.","DOI":"10.1007\/s00534-010-0264-6"},{"key":"74","doi-asserted-by":"crossref","unstructured":"74. Kudo M, Todo A, Ikekubo K, Yamamoto K, Vera DR, Stadalnik RC. Quantitative assessment of hepatocellular function through <i>in vivo<\/i> radioreceptor imaging with technetium 99m galactosyl human serum albumin. Hepatology. 1993; 17:814-819.","DOI":"10.1002\/hep.1840170511"},{"key":"75","doi-asserted-by":"crossref","unstructured":"75. Nagayama Y, Hokamura M, Taguchi N, Yokota Y, Osaki T, Ogasawara K, Shiraishi S, Yoshida R, Harai R, Kidoh M, Oda S, Nakaura T, Hirai T. Liver function estimation using multiphase hepatic CT: diagnostic performance of iodine-uptake and volumetric parameters. Eur Radiol. 2025; 35:5781\u20135791.","DOI":"10.1007\/s00330-025-11497-1"},{"key":"76","doi-asserted-by":"crossref","unstructured":"76. Mao Y, Du S, Ba J, <i>et al<\/i>. Using Dynamic 99mTc-GSA SPECT\/CT fusion images for hepatectomy planning and postoperative liver failure prediction. Ann Surg Oncol. 2015; 22:1301-1307.","DOI":"10.1245\/s10434-014-4117-4"},{"key":"77","unstructured":"77. Bennink RJ, Dinant S, Erdogan D, Heijnen BH, Straatsburg IH, van Vliet AK, van Gulik TM. Preoperative assessment of postoperative remnant liver function using hepatobiliary scintigraphy. J Nucl Med. 2004; 45:965-971."},{"key":"78","doi-asserted-by":"crossref","unstructured":"78. Trauner M, Meier PJ, Boyer JL. Molecular pathogenesis of cholestasis. N Engl J Med. 1998; 339:1217-1227.","DOI":"10.1056\/NEJM199810223391707"},{"key":"79","doi-asserted-by":"crossref","unstructured":"79. Erdogan D, Heijnen BH, Bennink RJ, Kok M, Dinant S, Straatsburg IH, Gouma DJ, van Gulik TM. Preoperative assessment of liver function: A comparison of 99mTc-Mebrofenin scintigraphy with indocyanine green clearance test. Liver Int. 2004; 24:117-123.","DOI":"10.1111\/j.1478-3231.2004.00901.x"},{"key":"80","doi-asserted-by":"crossref","unstructured":"80. Bakos A, Libor L, Urb\u00e1n S, G\u00e9czi T, Bukva M, H\u0151hn J, L\u00e1z\u00e1r G, Nagy A, Farkas I, Sipka G, P\u00e1vics L, Besenyi Z. Dynamic [(99m)Tc]Tc-mebrofenin SPECT\/CT in preoperative planning of liver resection: a prospective study. Sci Rep. 2024; 14:30305.","DOI":"10.1038\/s41598-024-81331-z"},{"key":"81","doi-asserted-by":"crossref","unstructured":"81. Johnson PJ, Berhane S, Kagebayashi C, <i>et al<\/i>. Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach-the ALBI grade. J Clin Oncol. 2015; 33:550-558.","DOI":"10.1200\/JCO.2014.57.9151"},{"key":"82","doi-asserted-by":"crossref","unstructured":"82. Hiraoka A, Kumada T, Michitaka K, Kudo M. Newly Proposed ALBI Grade and ALBI-T Score as Tools for Assessment of Hepatic Function and Prognosis in Hepatocellular Carcinoma Patients. Liver Cancer. 2019; 8:312-325.","DOI":"10.1159\/000494844"},{"key":"83","doi-asserted-by":"crossref","unstructured":"83. Reig M, Forner A, Rimola J, <i>et al<\/i>. BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update. J Hepatol. 2022; 76:681-693.","DOI":"10.1016\/j.jhep.2021.11.018"},{"key":"84","doi-asserted-by":"crossref","unstructured":"84. Toyoda H, Johnson PJ. The ALBI score: From liver function in patients with HCC to a general measure of liver function. JHEP Rep. 2022; 4:100557.","DOI":"10.1016\/j.jhepr.2022.100557"},{"key":"85","unstructured":"85. Japan Lcsgo. The general rules for the clinical and pathological study of primary liver cancer. The 5th edition. 2009; 24."},{"key":"86","doi-asserted-by":"crossref","unstructured":"86. Hiraoka A, Kumada T, Michitaka K, <i>et al<\/i>. Usefulness of albumin-bilirubin grade for evaluation of prognosis of 2584 Japanese patients with hepatocellular carcinoma. J Gastroenterol Hepatol. 2016; 31:1031-1036.","DOI":"10.1111\/jgh.13250"},{"key":"87","doi-asserted-by":"crossref","unstructured":"87. Hiraoka A, Michitaka K, Kumada T, Izumi N, Kadoya M, Kokudo N, Kubo S, Matsuyama Y, Nakashima O, Sakamoto M, Takayama T, Kokudo T, Kashiwabara K, Kudo M. Validation and Potential of Albumin-Bilirubin Grade and Prognostication in a Nationwide Survey of 46,681 Hepatocellular Carcinoma Patients in Japan: The Need for a More Detailed Evaluation of Hepatic Function. Liver Cancer. 2017; 6:325-336.","DOI":"10.1159\/000479984"},{"key":"88","unstructured":"88. Zhong CR, Qiu JL, Yuan YC, Qiu ZY, Li K, Wang CW, Shi YX, Li KR, Lin Z, Huang ZK, He W, Li BK, Yuan YF. A detailed assessment of liver function in patients with hepatocellular carcinoma <i>via<\/i> the modified albumin-bilirubin (mALBI) grade. Am J Cancer Res. 2022; 12:2711-2720."},{"key":"89","doi-asserted-by":"crossref","unstructured":"89. Hiraoka A, Kumada T, Tsuji K, <i>et al<\/i>. Validation of Modified ALBI Grade for More Detailed Assessment of Hepatic Function in Hepatocellular Carcinoma Patients: A Multicenter Analysis. Liver Cancer. 2019; 8:121-129.","DOI":"10.1159\/000488778"},{"key":"90","doi-asserted-by":"crossref","unstructured":"90. Kariyama K, Nouso K, Hiraoka A, <i>et al<\/i>. EZ-ALBI Score for Predicting Hepatocellular Carcinoma Prognosis. Liver Cancer. 2020; 9:734-743.","DOI":"10.1159\/000508971"},{"key":"91","doi-asserted-by":"crossref","unstructured":"91. Liu PH, Hsu CY, Hsia CY, Lee YH, Chiou YY, Huang YH, Lee FY, Lin HC, Hou MC, Huo TI. ALBI and PALBI grade predict survival for HCC across treatment modalities and BCLC stages in the MELD Era. J Gastroenterol Hepatol. 2017; 32:879-886.","DOI":"10.1111\/jgh.13608"},{"key":"92","doi-asserted-by":"crossref","unstructured":"92. Lu LH, Zhang YF, Mu-Yan C, Kan A, Zhong XP, Mei J, Ling YH, Li SH, Shi M, Wei W, Guo RP. Platelet-albumin-bilirubin grade: Risk stratification of liver failure, prognosis after resection for hepatocellular carcinoma. Dig Liver Dis. 2019; 51:1430-1437.","DOI":"10.1016\/j.dld.2019.04.006"},{"key":"93","doi-asserted-by":"crossref","unstructured":"93. Wang Q, Qiao W, Zhang H, Liu B, Li J, Zang C, Mei T, Zheng J, Zhang Y. Nomogram established on account of Lasso-Cox regression for predicting recurrence in patients with early-stage hepatocellular carcinoma. Front Immunol. 2022; 13:1019638.","DOI":"10.3389\/fimmu.2022.1019638"},{"key":"94","doi-asserted-by":"crossref","unstructured":"94. Wang Q, Sheng S, Xiong Y, Han M, Jin R, Hu C. Machine learning-based model for predicting tumor recurrence after interventional therapy in HBV-related hepatocellular carcinoma patients with low preoperative platelet-albumin-bilirubin score. Front Immunol. 2024; 15:1409443.","DOI":"10.3389\/fimmu.2024.1409443"},{"key":"95","doi-asserted-by":"crossref","unstructured":"95. Simpson AL, Geller DA, Hemming AW, Jarnagin WR, Clements LW, D&apos;Angelica MI, Dumpuri P, G\u00f6nen M, Zendejas I, Miga MI, Stefansic JD. Liver planning software accurately predicts postoperative liver volume and measures early regeneration. J Am Coll Surg. 2014; 219:199-207.","DOI":"10.1016\/j.jamcollsurg.2014.02.027"},{"key":"96","doi-asserted-by":"crossref","unstructured":"96. Zou H, Wen Y, Yuan K, Miao XY, Xiong L, Liu KJ. Combining albumin-bilirubin score with future liver remnant predicts post-hepatectomy liver failure in HBV-associated HCC patients. Liver Int. 2018; 38:494-502.","DOI":"10.1111\/liv.13514"},{"key":"97","doi-asserted-by":"crossref","unstructured":"97. Wai CT, Greenson JK, Fontana RJ, Kalbfleisch JD, Marrero JA, Conjeevaram HS, Lok AS. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology. 2003; 38:518-526.","DOI":"10.1053\/jhep.2003.50346"},{"key":"98","doi-asserted-by":"crossref","unstructured":"98. Hung HH, Su CW, Lai CR, Chau GY, Chan CC, Huang YH, Huo TI, Lee PC, Kao WY, Lee SD, Wu JC. Fibrosis and AST to platelet ratio index predict post-operative prognosis for solitary small hepatitis B-related hepatocellular carcinoma. Hepatol Int. 2010; 4:691-699.","DOI":"10.1007\/s12072-010-9213-3"},{"key":"99","doi-asserted-by":"crossref","unstructured":"99. Shen SL, Fu SJ, Chen B, Kuang M, Li SQ, Hua YP, Liang LJ, Guo P, Hao Y, Peng BG. Preoperative aspartate aminotransferase to platelet ratio is an independent prognostic factor for hepatitis B-induced hepatocellular carcinoma after hepatic resection. Ann Surg Oncol. 2014; 21:3802-3809.","DOI":"10.1245\/s10434-014-3771-x"},{"key":"100","doi-asserted-by":"crossref","unstructured":"100. Luo H, Li C, Chen L. Preoperative albumin-bilirubin grade combined with aspartate aminotransferase-to-platelet count ratio index predict outcomes of patients with hepatocellular carcinoma within Milan criteria after liver resection. Biosci Trends. 2019; 13:176-181.","DOI":"10.5582\/bst.2019.01088"},{"key":"101","doi-asserted-by":"crossref","unstructured":"101. Starlinger P, Ubl DS, Hackl H, Starlinger J, Nagorney DM, Smoot RL, Habermann EB, Cleary SP. Combined APRI\/ALBI score to predict mortality after hepatic resection. BJS Open. 2021; 5:zraa043.","DOI":"10.1093\/bjsopen\/zraa043"},{"key":"102","doi-asserted-by":"crossref","unstructured":"102. Vallet-Pichard A, Mallet V, Nalpas B, Verkarre V, Nalpas A, Dhalluin-Venier V, Fontaine H, Pol S. FIB-4: an inexpensive and accurate marker of fibrosis in HCV infection. Comparison with liver biopsy and fibrotest. Hepatology. 2007; 46:32-36.","DOI":"10.1002\/hep.21669"},{"key":"103","doi-asserted-by":"crossref","unstructured":"103. Toyoda H, Kumada T, Tada T, Kaneoka Y, Maeda A. A laboratory marker, FIB-4 index, as a predictor for long-term outcomes of hepatocellular carcinoma patients after curative hepatic resection. Surgery. 2015; 157:699-707.","DOI":"10.1016\/j.surg.2014.10.022"},{"key":"104","doi-asserted-by":"crossref","unstructured":"104. Zhou P, Chen B, Miao XY, Zhou JJ, Xiong L, Wen Y, Zou H. Comparison of FIB-4 Index and Child-Pugh Score in Predicting the Outcome of Hepatic Resection for Hepatocellular Carcinoma. J Gastrointest Surg. 2020; 24:823-831.","DOI":"10.1007\/s11605-019-04123-1"},{"key":"105","doi-asserted-by":"crossref","unstructured":"105. Sahani D, Mehta A, Blake M, Prasad S, Harris G, Saini S. Preoperative hepatic vascular evaluation with CT and MR angiography: implications for surgery. Radiographics. 2004; 24:1367-1380.","DOI":"10.1148\/rg.245035224"},{"key":"106","doi-asserted-by":"crossref","unstructured":"106. Kubota K, Makuuchi M, Kusaka K, Kobayashi T, Miki K, Hasegawa K, Harihara Y, Takayama T. Measurement of liver volume and hepatic functional reserve as a guide to decision-making in resectional surgery for hepatic tumors. Hepatology. 1997; 26:1176-1181.","DOI":"10.1002\/hep.510260514"},{"key":"107","doi-asserted-by":"crossref","unstructured":"107. Shukla A, Giri S. Portal Vein Thrombosis in Cirrhosis. J Clin Exp Hepatol. 2022; 12:965-979.","DOI":"10.1016\/j.jceh.2021.11.003"},{"key":"108","doi-asserted-by":"crossref","unstructured":"108. Heo S, Lee SS, Choi SH, Kim DW, Park HJ, Kim SY, Lee SJ, Kim KM, Shin YM. CT Rule-in and Rule-out Criteria for Clinically Significant Portal Hypertension in Chronic Liver Disease. Radiology. 2023; 309:e231208.","DOI":"10.1148\/radiol.231208"},{"key":"109","doi-asserted-by":"crossref","unstructured":"109. Tu R, Xia LP, Yu AL, Wu L. Assessment of hepatic functional reserve by cirrhosis grading and liver volume measurement using CT. World J Gastroenterol. 2007; 13:3956-3961.","DOI":"10.3748\/wjg.v13.i29.3956"},{"key":"110","doi-asserted-by":"crossref","unstructured":"110. Son JH, Lee SS, Lee Y, Kang BK, Sung YS, Jo S, Yu E. Assessment of liver fibrosis severity using computed tomography-based liver and spleen volumetric indices in patients with chronic liver disease. Eur Radiol. 2020; 30:3486-3496.","DOI":"10.1007\/s00330-020-06665-4"},{"key":"111","doi-asserted-by":"crossref","unstructured":"111. Yan C, Han X, Liang X, Jia J, Xu Y, Zhao L. Non-invasive evaluation of esophageal varices in patients with liver cirrhosis using low-dose splenic perfusion CT. Eur J Radiol. 2022; 152:110326.","DOI":"10.1016\/j.ejrad.2022.110326"},{"key":"112","doi-asserted-by":"crossref","unstructured":"112. Romero-Crist\u00f3bal M, Clemente-S\u00e1nchez A, Ram\u00f3n E, <i>et al<\/i>. CT-derived liver and spleen volume accurately diagnose clinically significant portal hypertension in patients with hepatocellular carcinoma. JHEP Rep. 2023; 5:100645.","DOI":"10.1016\/j.jhepr.2022.100645"},{"key":"113","doi-asserted-by":"crossref","unstructured":"113. Bak S, Kim JE, Bae K, Cho JM, Choi HC, Park MJ, Choi HY, Shin HS, Lee SM, Kim HO. Quantification of liver extracellular volume using dual-energy CT: utility for prediction of liver-related events in cirrhosis. Eur Radiol. 2020; 30:5317-5326.","DOI":"10.1007\/s00330-020-06876-9"},{"key":"114","doi-asserted-by":"crossref","unstructured":"114. Morita K, Nishie A, Ushijima Y, Takayama Y, Fujita N, Kubo Y, Ishimatsu K, Yoshizumi T, Maehara J, Ishigami K. Noninvasive assessment of liver fibrosis by dual-layer spectral detector CT. Eur J Radiol. 2021; 136:109575.","DOI":"10.1016\/j.ejrad.2021.109575"},{"key":"115","doi-asserted-by":"crossref","unstructured":"115. Varenika V, Fu Y, Maher JJ, Gao D, Kakar S, Cabarrus MC, Yeh BM. Hepatic fibrosis: evaluation with semiquantitative contrast-enhanced CT. Radiology. 2013; 266:151-158.","DOI":"10.1148\/radiol.12112452"},{"key":"116","doi-asserted-by":"crossref","unstructured":"116. Nagayama Y, Kato Y, Inoue T, Nakaura T, Oda S, Kidoh M, Ikeda O, Hirai T. Liver fibrosis assessment with multiphasic dual-energy CT: diagnostic performance of iodine uptake parameters. Eur Radiol. 2021; 31:5779-5790.","DOI":"10.1007\/s00330-021-07706-2"},{"key":"117","doi-asserted-by":"crossref","unstructured":"117. Barr RG, Wilson SR, Rubens D, Garcia-Tsao G, Ferraioli G. Update to the Society of Radiologists in Ultrasound Liver Elastography Consensus Statement. Radiology. 2020; 296:263-274.","DOI":"10.1148\/radiol.2020192437"},{"key":"118","doi-asserted-by":"crossref","unstructured":"118. Duan T, Jiang HY, Ling WW, Song B. Noninvasive imaging of hepatic dysfunction: A state-of-the-art review. World J Gastroenterol. 2022; 28:1625-1640.","DOI":"10.3748\/wjg.v28.i16.1625"},{"key":"119","doi-asserted-by":"crossref","unstructured":"119. Sande JA, Verjee S, Vinayak S, Amersi F, Ghesani M. Ultrasound shear wave elastography and liver fibrosis: A Prospective Multicenter Study. World J Hepatol. 2017; 9:38-47.","DOI":"10.4254\/wjh.v9.i1.38"},{"key":"120","doi-asserted-by":"crossref","unstructured":"120. Nguyen-Khac E, Thiele M, Voican C, <i>et al<\/i>. Non-invasive diagnosis of liver fibrosis in patients with alcohol-related liver disease by transient elastography: an individual patient data meta-analysis. Lancet Gastroenterol Hepatol. 2018; 3:614-625.","DOI":"10.1016\/S2468-1253(18)30124-9"},{"key":"121","doi-asserted-by":"crossref","unstructured":"121. Selvaraj EA, M\u00f3zes FE, Jayaswal ANA, <i>et al<\/i>. Diagnostic accuracy of elastography and magnetic resonance imaging in patients with NAFLD: A systematic review and meta-analysis. J Hepatol. 2021; 75:770-785.","DOI":"10.1016\/j.jhep.2021.04.044"},{"key":"122","doi-asserted-by":"crossref","unstructured":"122. Berzigotti A, Seijo S, Arena U, Abraldes JG, Vizzutti F, Garc\u00eda-Pag\u00e1n JC, Pinzani M, Bosch J. Elastography, spleen size, and platelet count identify portal hypertension in patients with compensated cirrhosis. Gastroenterology. 2013; 144:102-111.e101.","DOI":"10.1053\/j.gastro.2012.10.001"},{"key":"123","doi-asserted-by":"crossref","unstructured":"123. Berzigotti A. Non-invasive evaluation of portal hypertension using ultrasound elastography. J Hepatol. 2017; 67:399-411.","DOI":"10.1016\/j.jhep.2017.02.003"},{"key":"124","doi-asserted-by":"crossref","unstructured":"124. Long H, Zhong X, Su L, Huang T, Duan Y, Ke W, Xie X, Lin M. Liver Stiffness Measured by Two-Dimensional Shear Wave Elastography for Predicting Symptomatic Post-hepatectomy Liver Failure in Patients with Hepatocellular Carcinoma. Ann Surg Oncol. 2022; 29:327-336.","DOI":"10.1245\/s10434-021-10563-4"},{"key":"125","doi-asserted-by":"crossref","unstructured":"125. Cheng GW, Fang Y, Xue LY, Zhang Y, Xie XY, Qiao XH, Li XQ, Guo J, Ding H. Nomogram based on liver stiffness and spleen area with ultrasound for posthepatectomy liver failure: A multicenter study. World J Gastroenterol. 2024; 30:3314-3325.","DOI":"10.3748\/wjg.v30.i27.3314"},{"key":"126","unstructured":"126. Shastri M, Kulkarni S, Patell R, Jasdanwala S. Portal vein Doppler: a tool for non-invasive prediction of esophageal varices in cirrhosis. J Clin Diagn Res. 2014; 8:MC12-15."},{"key":"127","doi-asserted-by":"crossref","unstructured":"127. Elkenawy YN, Elarabawy RA, Ahmed LM, Elsawy AA. Portal vein flow velocity as a possible fast noninvasive screening tool for esophageal varices in cirrhotic patients. JGH Open. 2020; 4:589-594.","DOI":"10.1002\/jgh3.12301"},{"key":"128","doi-asserted-by":"crossref","unstructured":"128. Evrimler S, Swensson JK, Are VS, Tirkes T, Vuppalanchi R, Akisik F. Quantitative assessment of disease severity of primary sclerosing cholangitis with T1 mapping and extracellular volume imaging. Abdom Radiol (NY). 2021; 46:2433-2443.","DOI":"10.1007\/s00261-020-02839-2"},{"key":"129","doi-asserted-by":"crossref","unstructured":"129. Jhaveri KS, Hosseini-Nik H, Sadoughi N, Janssen H, Feld JJ, Fischer S, Menezes R, Cheung AC. The development and validation of magnetic resonance elastography for fibrosis staging in primary sclerosing cholangitis. Eur Radiol. 2019; 29:1039-1047.","DOI":"10.1007\/s00330-018-5619-4"},{"key":"130","doi-asserted-by":"crossref","unstructured":"130. Tafur M, Cheung A, Menezes RJ, Feld J, Janssen H, Hirschfield GM, Jhaveri KS. Risk stratification in primary sclerosing cholangitis: comparison of biliary stricture severity on MRCP versus liver stiffness by MR elastography and vibration-controlled transient elastography. Eur Radiol. 2020; 30:3735-3747.","DOI":"10.1007\/s00330-020-06728-6"},{"key":"131","doi-asserted-by":"crossref","unstructured":"131. Aleksakhina SN, Imyanitov EN. Cancer Therapy Guided by Mutation Tests: Current Status and Perspectives. Int J Mol Sci. 2021; 22:10931.","DOI":"10.3390\/ijms222010931"},{"key":"132","doi-asserted-by":"crossref","unstructured":"132. Tan AC, Tan DSW. Targeted Therapies for Lung Cancer Patients With Oncogenic Driver Molecular Alterations. J Clin Oncol. 2022; 40:611-625.","DOI":"10.1200\/JCO.21.01626"},{"key":"133","doi-asserted-by":"crossref","unstructured":"133. Casolino R, Beer PA, Chakravarty D, Davis MB, Malapelle U, Mazzarella L, Normanno N, Pauli C, Subbiah V, Turnbull C, Westphalen CB, Biankin AV. Interpreting and integrating genomic tests results in clinical cancer care: Overview and practical guidance. CA Cancer J Clin. 2024; 74:264-285.","DOI":"10.3322\/caac.21825"},{"key":"134","doi-asserted-by":"crossref","unstructured":"134. Tsilimigras DI, Kurzrock R, Pawlik TM. Molecular Testing and Targeted Therapies in Hepatobiliary Cancers: A Review. JAMA Surg. 2025; 160:576-585.","DOI":"10.1001\/jamasurg.2025.0242"}],"container-title":["BioScience Trends"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bst\/20\/2\/20_2026.01032\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,23]],"date-time":"2026-05-23T03:27:51Z","timestamp":1779506871000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bst\/20\/2\/20_2026.01032\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,30]]},"references-count":134,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.5582\/bst.2026.01032","relation":{},"ISSN":["1881-7815","1881-7823"],"issn-type":[{"value":"1881-7815","type":"print"},{"value":"1881-7823","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,30]]},"article-number":"2026.01032"}}